U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281495) titled 'Taldefgrobep Alfa in Adults With Overweight and Obesity' on Dec. 04.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Study Start Date: Nov. 24
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Taldefgrobep Alfa
Subcutaneous injection administered once each week
DRUG: Placebo
Subcutaneous injection (matching placebo) administered once each week
DRUG: Taldefgrobep Alfa
Subcutaneous injection administered...